Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090957079> ?p ?o ?g. }
- W2090957079 endingPage "706" @default.
- W2090957079 startingPage "699" @default.
- W2090957079 abstract "Community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) are very relevant pathologies among elderly people (≥ 65 y old), with a consequent high disease burden. Immunization with the 23-valent pneumococcal polysaccharide vaccine (PPV23) has been differently implemented in the Italian regions in the past years, reaching overall low coverage rates even in those with medical indications. In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) became available and recommended in the universal Italian infant immunization program. Since October 2012, indications for use of PCV13 were extended to subjects ≥ 50 y to prevent invasive pneumococcal diseases. The Italian decision makers should now revise regional indications for the prevention of pneumococcal diseases in the elderly. Pharmaco-economic analyses represent a useful tool to value the feasibility of new immunization programs and their sustainability. Therefore, an ad hoc population model was developed in order to value the clinical and economic impact of an adult pneumococcal vaccination program in Italy. Particularly, different immunization scenarios were modeled: vaccination of 65 y-olds (1 cohort strategy), simultaneous vaccination of people aged 65 and 70 y (double cohort strategy) and, lastly, immunization of people aged 65, 70 and 75 y (triple cohort strategy), thus leading to the vaccination of 5, 10 and 15 cohorts during the 5 y of the program. In addition, the administration of a PPV23 dose one year after PCV13 was evaluated, in order to verify the economic impact of the supplemental serotype coverage in elderly people. The mathematical model valued the clinical impact of PCV13 vaccination on the number of bacteraemic pneumococcal pneumonia (BPP) and pneumococcal meningitis (PM) cases, and related hospitalizations and deaths. Although PCV13 is not yet formally indicated for the prevention of pneumococcal CAP by the European Medicine Agency (differently from FDA, whose indications include all pneumococcal diseases in subjects ≥ 50 y), the model calculated also the possible impact of vaccination on CAP cases (non-bacteraemic), considering the rate of this disease due to S. pneumoniae. The results of the analysis show that, in Italy, an age-based PCV13 vaccination program in elderly people is cost-effective from the payer perspective, with costs per QALY ranging from 17,000 to 22,000 Euro, according to the adopted vaccination strategy. The subsequent PPV23 offer results in an increment of costs per QALY (from 21,000 to 28,000 Euro, according to the vaccination strategy adopted). Pneumococcal vaccination using the conjugate vaccine turned out to be already favorable in the second year of implementation, with incremental costs per QALY comparable to those of other already adopted prevention activities in Italy (for instance, universal HPV vaccination of 12 y-old girls), with further benefits obtained when extending the study period beyond the 5-y horizon of our analysis." @default.
- W2090957079 created "2016-06-24" @default.
- W2090957079 creator A5025773734 @default.
- W2090957079 creator A5027857994 @default.
- W2090957079 creator A5035959176 @default.
- W2090957079 creator A5051550337 @default.
- W2090957079 creator A5053188061 @default.
- W2090957079 creator A5091245642 @default.
- W2090957079 date "2013-03-18" @default.
- W2090957079 modified "2023-10-17" @default.
- W2090957079 title "Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy" @default.
- W2090957079 cites W2000129666 @default.
- W2090957079 cites W2006700528 @default.
- W2090957079 cites W2023690749 @default.
- W2090957079 cites W2024634994 @default.
- W2090957079 cites W2025651568 @default.
- W2090957079 cites W2049386698 @default.
- W2090957079 cites W2059506670 @default.
- W2090957079 cites W2070432392 @default.
- W2090957079 cites W2070935374 @default.
- W2090957079 cites W2089041217 @default.
- W2090957079 cites W2090602059 @default.
- W2090957079 cites W2103853305 @default.
- W2090957079 cites W2110052872 @default.
- W2090957079 cites W2110155476 @default.
- W2090957079 cites W2111717771 @default.
- W2090957079 cites W2112075440 @default.
- W2090957079 cites W2117239980 @default.
- W2090957079 cites W2117373567 @default.
- W2090957079 cites W2149176649 @default.
- W2090957079 cites W2149410588 @default.
- W2090957079 cites W2166448515 @default.
- W2090957079 cites W2168838429 @default.
- W2090957079 doi "https://doi.org/10.4161/hv.23268" @default.
- W2090957079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3891731" @default.
- W2090957079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23295824" @default.
- W2090957079 hasPublicationYear "2013" @default.
- W2090957079 type Work @default.
- W2090957079 sameAs 2090957079 @default.
- W2090957079 citedByCount "38" @default.
- W2090957079 countsByYear W20909570792013 @default.
- W2090957079 countsByYear W20909570792014 @default.
- W2090957079 countsByYear W20909570792015 @default.
- W2090957079 countsByYear W20909570792016 @default.
- W2090957079 countsByYear W20909570792017 @default.
- W2090957079 countsByYear W20909570792018 @default.
- W2090957079 countsByYear W20909570792019 @default.
- W2090957079 countsByYear W20909570792020 @default.
- W2090957079 countsByYear W20909570792021 @default.
- W2090957079 countsByYear W20909570792022 @default.
- W2090957079 countsByYear W20909570792023 @default.
- W2090957079 crossrefType "journal-article" @default.
- W2090957079 hasAuthorship W2090957079A5025773734 @default.
- W2090957079 hasAuthorship W2090957079A5027857994 @default.
- W2090957079 hasAuthorship W2090957079A5035959176 @default.
- W2090957079 hasAuthorship W2090957079A5051550337 @default.
- W2090957079 hasAuthorship W2090957079A5053188061 @default.
- W2090957079 hasAuthorship W2090957079A5091245642 @default.
- W2090957079 hasBestOaLocation W20909570791 @default.
- W2090957079 hasConcept C126322002 @default.
- W2090957079 hasConcept C187212893 @default.
- W2090957079 hasConcept C203014093 @default.
- W2090957079 hasConcept C22070199 @default.
- W2090957079 hasConcept C2778866548 @default.
- W2090957079 hasConcept C2779664119 @default.
- W2090957079 hasConcept C2779892413 @default.
- W2090957079 hasConcept C2780801004 @default.
- W2090957079 hasConcept C2781253189 @default.
- W2090957079 hasConcept C2908647359 @default.
- W2090957079 hasConcept C3020803494 @default.
- W2090957079 hasConcept C523546767 @default.
- W2090957079 hasConcept C54355233 @default.
- W2090957079 hasConcept C71924100 @default.
- W2090957079 hasConcept C72563966 @default.
- W2090957079 hasConcept C86803240 @default.
- W2090957079 hasConcept C8891405 @default.
- W2090957079 hasConcept C99454951 @default.
- W2090957079 hasConceptScore W2090957079C126322002 @default.
- W2090957079 hasConceptScore W2090957079C187212893 @default.
- W2090957079 hasConceptScore W2090957079C203014093 @default.
- W2090957079 hasConceptScore W2090957079C22070199 @default.
- W2090957079 hasConceptScore W2090957079C2778866548 @default.
- W2090957079 hasConceptScore W2090957079C2779664119 @default.
- W2090957079 hasConceptScore W2090957079C2779892413 @default.
- W2090957079 hasConceptScore W2090957079C2780801004 @default.
- W2090957079 hasConceptScore W2090957079C2781253189 @default.
- W2090957079 hasConceptScore W2090957079C2908647359 @default.
- W2090957079 hasConceptScore W2090957079C3020803494 @default.
- W2090957079 hasConceptScore W2090957079C523546767 @default.
- W2090957079 hasConceptScore W2090957079C54355233 @default.
- W2090957079 hasConceptScore W2090957079C71924100 @default.
- W2090957079 hasConceptScore W2090957079C72563966 @default.
- W2090957079 hasConceptScore W2090957079C86803240 @default.
- W2090957079 hasConceptScore W2090957079C8891405 @default.
- W2090957079 hasConceptScore W2090957079C99454951 @default.
- W2090957079 hasIssue "3" @default.
- W2090957079 hasLocation W20909570791 @default.
- W2090957079 hasLocation W20909570792 @default.